Monte Rosa gets $50 million milestone as Novartis starts Phase 2
Monte Rosa said it received a $50 million milestone payment after Novartis started a Phase 2 study of MRT-6160, also known as DDY391, in Sjögren’s disease.
Key Highlights:Original SEC Filing: Monte Rosa Therapeutics, Inc. [ GLUE ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider…